Abstract:Abstract Background: Aptamer-drug conjugates are promising to be applied to targeted cancer therapy, in which anticancer drugs were selectively delivered into cognate cancerous cells, but not to healthy tissues, in order to reduce side effects and enhance therapeutic efficacy. Methodology/Principal Findings: In this study, the technology of drug-DNA adduct (DDA) was utilized to prepare drug-aptamer conjugates. Particularly, an anticancer drug, Doxorubicin (Dox), was conjugated with AS1411, a DNA aptamer which specifically recognizes human hepatocellular carcinoma Huh7 cells. The technology enabled a simple and high-payload conjugation of drugs onto aptamers. The resultant AS1411-Dox adduct maintained selectively recognition ability to target liver cancer cells with strong binding affinity (demonstrated by flow cytometry), was able to selectively deliver the conjugated Dox into target cancer cells (observed with confocal microscopy), and exhibited selective and potent cytotoxicity in target liver cancer cells (evaluated by MTS cell viability assay). More importantly, as the first of its kind, AS1411-Dox adduct demonstrated selectively antitumor therapeutic efficacy of this drug-aptamer conjugation technology in a mouse model. The ability of drug-aptamer adducts to deliver anticancer drugs into target cancer cells, while inhibiting nonspecific drug uptake in nontarget cells, enables this technology promising to be implemented in targeted cancer therapy. Conclusions/Significance: Given the demonstrated ability of targeted liver cancer therapy combined with the aforementioned advantageous features as a simple preparation, the high drug payload capacity, and the wide applicability, this novel drug-DNA adduct technology is anticipated for wide implications for targeted cancer therapy. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B97. Citation Format: Thu Le Trinh, Guizhi Zhu, Xilin Xiao, Xiaokui Zhang, Kwame Sefah, Weihong Tan, Chen Liu. AS1411-Doxorubicin adduct for targeted liver cancer therapy. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B97.

Design, synthesis, and in vitro antitumor activity of a transferrin receptor‐targeted peptide–doxorubicin conjugate

New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity

Preparation and Antitumor Activity of Bfgf-Mediated Active Targeting Doxorubicin Microbubbles

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Plasmid Porf-Htrail and Doxorubicin Co-Delivery Targeting to Tumor Using Peptide-Conjugated Polyamidoamine Dendrimer

A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.

Synthesis, Characterization, Cellular Uptake, and in Vitro Anticancer Activity of Fullerenol-Doxorubicin Conjugates

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles

Targeted Delivery Of Chemotherapy Agents Using A Liver Cancer-Specific Aptamer

Peptide-Conjugated Pamam for Targeted Doxorubicin Delivery to Transferrin Receptor Overexpressed Tumors

Increased Delivery of Doxorubicin into Tumor Cells Using Extracellularly Activated Tat Functionalized Liposomes: in Vitro and in Vivo Study

[Targeted drug delivery system for doxorubicin based on a specific peptide and phospholipid nanoparticles]

The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy

Synergistic Effect of Reduced Polypeptide Micelle for Co-Delivery of Doxorubicin and Trail Against Drug-Resistance in Breast Cancer

Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.

Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT

pH-sensitive doxorubicin-loaded polymeric nanocomplex based on β-cyclodextrin for liver cancer-targeted therapy.

Folate-decorated Maleilated Pullulan–doxorubicin Conjugate for Active Tumor-Targeted Drug Delivery

A Smart Tumor Targeting Peptide-Drug Conjugate, Phlip-Ss-Dox: Synthesis and Cellular Uptake on Mcf-7 and Mcf-7/Adr Cells

Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells.

Abstract B97: AS1411-Doxorubicin Adduct for Targeted Liver Cancer Therapy.